Develop business Strategies Of Myelofibrosis Market 2025
"The
Latest Research Report OpportunityAnalyzer: Myelofibrosis -
Opportunity Analysis and Forecasts to 2025 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Myelofibrosis Market
Myelofibrosis (MF) is a rare blood
disorder, which is characterized by bone marrow fibrosis. Currently,
there is only one approved drug, Incyte/Novartis Jakafi
(ruxolitinib), for the treatment of MF, and other conventional
therapies used in MF are off-label. However, none of these drugs are
curative, and the only potentially curative intervention is
allogeneic stem cell transplant (allo-SCT), which is available to a
very small percentage of eligible patients because of the high risk
of morbidity and mortality. Therefore, there is a huge unmet need for
the treatment of MF.
This report highlights the
significant unmet need for novel drug treatment for MF, both to
alleviate MF-associated complications and to reverse the disease
course, across the seven major markets; it also discusses the
associated commercial opportunities for new market entrants to gain a
foothold in the market. GlobalData anticipate the MF market to almost
double, from $545.2m to $1.01 billion, over the forecast period of
2015-2025. The key drivers wills be the launch of pipeline drugs,
increasing incidence and an increase in the use of drugs for
splenomegaly and constitutional symptoms in the 5EU and Japan.
Highlights
Get Sample Copy Of This Report
@ https://www.marketresearchreports.biz/sample/sample/959624
Key Questions Answered
- The MF market has high unmet
need. What are the main unmet needs in this market? How will the
drugs under development fulfil the unmet needs of the MF market?
- There are three middle- to
late-stage MF pipeline drugs expected to launch during the forecast
period. Will these drugs make a significant impact on the MF market?
Which of these drugs will have the deepest patient penetration and
highest peak sales, and why?
- The current MF market is
dominated by one JAK inhibitor, Jakafi. How will the launch of
pipeline drugs with novel mechanism of action change this? How will
the way MF patients are treated change over the next years? What are
the key drivers and barriers to this change?
Key Findings
- The launch of premium priced
products, in particular second-line treatments for patients who are
refractory to Jakafi, will be the main drivers of growth in he MF
market.
- There are high unmet needs in
MF. The biggest unmet need is for curative treatments. The unmet
needs will only be partially addressed by the major pipeline drugs.
In addition, there are currently no approved or major pipeline drugs
for MF-associated anemia. Any drug that can get approved in this
setting can expect a lucrative return.
- Key Opinion Leaders urged pharma
companies to focus their R&D strategies on trying to reverse the
disease course of MF. This will involve collaborating with academics
to identify new molecular targets.
- One key R&D strategy will be
developing drugs that reverse bone marrow fibrosis.
Scope
- Overview of MF, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis,
treatment guidelines and disease management.
- Annualized MF therapeutics
market revenue, average cost of therapy and treatment usage pattern
data from 2015 and forecast for seven years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the MF
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of middle- to late-stage pipeline
drugs.
- Analysis of the current and
future market competition in the global MF therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the global MF
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global MF therapeutics
market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
MF therapeutics market from 2015-2025.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/959624
Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology
21
3.1.1 Etiology 22
3.1.2 Pathophysiology 23
3.2 Classification and Prognosis
25
3.3 Symptoms 27
3.4 Quality of Life 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities
32
4.2 Global Trends 34
4.2.1 US 35
4.2.2 5EU 37
4.2.3 Japan 37
4.3 Forecast Methodology 37
4.3.1 Sources Used 37
4.3.2 Forecast Assumptions and
Methods 48
4.3.3 Sources Not Used 61
4.4 Epidemiological Forecast of
Myelofibrosis (2015-2025) 62
4.4.1 Diagnosed Incident Cases 62
4.4.2 Diagnosed Prevalent Cases 77
4.5 Discussion 90
4.5.1 Epidemiological Forecast
Insight 90
4.5.2 Limitations of the Analysis
91
4.5.3 Strengths of the Analysis 92
5 Current Treatment Options 93
5.1 Overview 93
5.2 Diagnosis and Treatment 94
5.2.1 Diagnosis 94
5.2.2 Treatment Guidelines and
Leading Prescribed Drugs 99
5.2.3 Clinical Practice 100
5.3 Major Brands - JAK Inhibitors
108
5.3.1 Jakafi (Ruxolitinib) 108
5.4 Conventional Medical Therapy
(Off-Label) 120
5.4.1 Cytoreductive Drugs 120
5.4.2 Androgen Therapies 121
5.4.3 Erythropoiesis-Stimulating
Agents 124
5.4.4 Immunomodulatory Imide Drugs
124
5.4.5 Anti-fibrotic Agents 126
6 Unmet Needs Assessment and
Opportunity Analysis 127
6.1 Overview 127
6.2 Development of Curative
Treatments 128
6.2.1 Unmet Need 128
6.2.2 Gap Analysis 129
6.2.3 Opportunity 130
6.3 Treatments for MF Patients
with Severe Thrombocytopenia 131
6.3.1 Unmet Need 131
6.3.2 Gap Analysis 131
6.3.3 Opportunity 132
6.4 Second-Line Treatments for MF
Patients Refractory to Jakafi 132
6.4.1 Unmet Need 132
6.4.2 Gap Analysis 133
6.4.3 Opportunity 133
6.5 Approved Treatment for
MF-Associated Anemia 134
6.5.1 Unmet Need 134
6.5.2 Gap Analysis 134
6.5.3 Opportunity 135
6.6 Effective Treatments with
Better Long-Term Safety 135
6.6.1 Unmet Need 135
6.6.2 Gap Analysis 136
6.6.3 Opportunity 137
7 Research and Development
Strategies 138
7.1 Overview 138
7.1.1 Targeting the JAK/STAT
Signaling Pathway 138
7.1.2 Developing Drugs that
Reverse Bone Marrow Fibrosis 139
7.1.3 Second-Line Therapies for
Patients After Jakafi Treatment 139
7.1.4 Novel Drugs in Combination
with Jakafi 140
7.1.5 Immuno-oncology Approach 141
7.2 Clinical Trial Design 142
7.2.1 Shifting Paradigm of Primary
Endpoints Selection 144
7.2.2 Inclusion of MF Patients
with Severe Thrombocytopenia 145
7.2.3 Selection of an Appropriate
Comparator 146
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment